Institutional members access full text with Ovid®

Share this article on:

Scleral Contact Lenses May Help Where Other Modalities Fail

Segal, Ori M.D.; Barkana, Yaniv M.D.; Hourovitz, Dafna M.D.; Behrman, Shmuel B.Sc., F.B.C.O.; Kamun, Yifaa; Avni, Isaac M.D.; Zadok, David M.D.

Clinical Sciences

Purpose. To describe the vision-correcting and therapeutic benefits of gas-permeable scleral contact lenses (GP-ScCL) in the management of irregular corneal surface disorders and ocular surface diseases.

Methods. The charts of 48 consecutive patients (66 eyes) whose management included the use of GP-ScCL were reviewed.

Results. The most common indication for fitting the lenses was keratoconus in patients who had to stop wearing other types of corneal lenses (44 eyes, 74.6%). Other indications included extreme corneal irregularity after penetrating keratoplasty, nonhealing corneal ulcer, postoperative dry eye syndrome following laser in situ keratomileusis (LASIK), severe exposure keratitis and acid burn. Mean follow-up was 17 months (range, 2–96). Mean wearing time of the GP-ScCL was 16.2 hours per day (range, 3–18). Visual acuity of 20/40 or better was achieved in 90.9% of keratoconus patients and in 81.8% of postkeratoplasty patients. A gain of two or more Snellen lines was observed in 94.5% of eyes treated for improving vision. Marked subjective improvement in quality of life was reported by 86% of the patients, mainly as a result of improvement in their visual function and reduction in discomfort. Five patients (seven eyes) failed to wear GP-ScCL.

Conclusion. GP-ScCL can provide successful and safe visual and therapeutic solutions for ocular conditions when conventional contact lenses and medical treatment have failed and where surgery is undesirable or contraindicated.

From the Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin, Israel.

Submitted October 25, 2002.

Revision received February 24, 2003.

Accepted March 4, 2003.

Address correspondence and reprint request to Ori Segal, M.D., Department of Ophthalmology, Assaf Harofeh Medical Center, Zerifin 70300, Israel. E-mail: orisegal@netvision.net.il

© 2003 Lippincott Williams & Wilkins, Inc.